I received my Ph.D. in Biomedical Sciences from Marshall University in 2013. My research thesis aimed at evaluating the use of omega-3 fatty acids as chemo-preventive and chemo-therapeutic agents for the treatment of B-Cell Chronic Lymphocytic Leukemia. Upon completion of my Ph.D. thesis, I dedicated myself to the study and understanding of altered tumor metabolism. This led me to my first post-doctoral fellowship position at the NIH West Coast Metabolomics Center under the mentorship of Professor Oliver Fiehn. During this time I became well-versed in the field of untargeted/targeted metabolomics, mass spectrometry and stable-isotope resolved metabolomics. This knowledge base was applied to diverse studies examining metabolic perturbations in various biological matrices under different pathological states including blood-based biomarker discovery for early diagnosis of lung cancer. I have since taken on a new position as a post-doctorate fellow working at Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer at University of Texas, MD Anderson. My primary interests lie in the use of metabolomics for the discovery and validation of blood-derived metabolite biomarkers for early diagnosis of cancer, with particular emphasis on lung cancer. Secondary aims consist of using a systems biology approach via integration of multiple 'omic' platforms and basic research methodologies to interrogate altered tumor metabolism and how this can be used to strengthen biomarker discovery.